Deprescribing Machine Learning ITR Aim-II (sIRB)

Deprescribing Machine Learning ITR Aim-II (sIRB)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

Everyone who shows interest and passes an early screening will be invited to join all three design group sessions. At the first session, the team will explain what the sessions are about, the benefits and risks, and ask people to give consent. They will also complete some short assessments. The total time for all three sessions will be about three hours, and the team will schedule them at times that work best for the doctors, patients, and caregivers taking part. All three sessions will be held online. In these sessions, doctors and patient or caregiver participants will help design and improve a new tool that supports medical decision making.

Who Can Participate?

Eligibility

Clinicians can join this study if they are 18 years or older, have worked at Duke for at least one year, and give consent. They will be recruited from primary care, geriatrics, psychiatry, and neurology. Patients can join if they are 65 years or older, go to the Duke Geriatrics Evaluation and Treatment Clinic, and take at least one medicine that affects the central nervous system. Patients and caregivers may be selected together when a caregiver is involved.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Looking for Healthy Participants
Yes

What is Involved?

Description

The goal of this part of the study is to design and test a tool that helps doctors and patients understand computer generated advice about stopping or lowering medicines. The tool should be easy to understand, clear about how it makes decisions, and something people can trust. This work uses what was learned in the first part of the study, where computer models created personalized treatment recommendations.

Locations

Remote/online

Compensation

Yes

Spanish Materials Available

No

Study Details

Full Title

Deprescribing Decision-Making using Machine Learning Individualized Treatment Rules to Improve CNS Polypharmacy- Aim-II (sIRB)

Principal Investigator

Juliessa
Pavon

Protocol Number

PRO00119273

Enrollment Status

Pending Open to Enrollment